BioWorld

Feb. 5, 2008

View Archived Issues

Increasing Complexity in Deals Can Be a Blessing or a Curse

Read More

IDM Pops on Paper Showing Survival Benefit for Mifamurtide

Read More

Centocor's Ustekinumab Shows Good Data in Plaque Psoriasis

Read More

Financings Roundup

Read More

Clinic Roundup

Read More

Amgen Unloads 13 Molecules in $1B-plus Deal with Takeda

Amgen Inc. is selling the Japanese rights to 13 molecules, including the FDA-approved colorectal drug Vectibix (panitumumab), to Takeda Pharmaceutical Co. Ltd. in a deal potentially worth more than $1 billion. (BioWorld Today) Read More

Amira Inks $425M FLAP Inhibitor Deal with GSK

Read More

Other News To Note

Read More